Accéder au contenu
MilliporeSigma
Toutes les photos(1)

Key Documents

View All Documentation

SML0150

Sigma-Aldrich

Tolcapone

≥98% (HPLC)

Synonyme(s) :

3,4-Dihydroxy-4′-methyl-5-nitrobenzophenone, Ro 40-7592

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C14H11NO5
Numéro CAS:
134308-13-7
Poids moléculaire :
273.24
Numéro MDL:
MFCD00866569
Code UNSPSC :
12352200
ID de substance PubChem :
329825198
Nomenclature NACRES :
NA.77

Pureté

≥98% (HPLC)

Forme

powder

Conditions de stockage

desiccated

Couleur

yellow

Solubilité

DMSO: ≥15 mg/mL

Auteur

Roche

Température de stockage

2-8°C

Chaîne SMILES 

Cc1ccc(cc1)C(=O)c2cc(O)c(O)c(c2)[N+]([O-])=O

InChI

1S/C14H11NO5/c1-8-2-4-9(5-3-8)13(17)10-6-11(15(19)20)14(18)12(16)7-10/h2-7,16,18H,1H3

Clé InChI

MIQPIUSUKVNLNT-UHFFFAOYSA-N

Informations sur le gène

human ... COMT(1312)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Application

Tolcapone may be used in COMT-mediated cell signaling studies.
Tolcapone has been used in methyltransferase assay in human embryonic kidney 293 cells.

Actions biochimiques/physiologiques

Inhibition of catechol-O-methyltransferase by tolcapone increases the half-life and bioavailabilty of levodopa. It therefore is an effective adjunctive therapy in patients with Parkinson′s disease with motor response fluctuations.
Tolcapone is an orally active catechol-O-methyltransferase (COMT) inhibitor. It inhibits both central and peripheral COMT. Tolcapone crosses the blood-brain barrier, and has been used for L-DOPA adjunct therapy in the treatment of Parkinson′s Disease.

Caractéristiques et avantages

This compound was developed by Roche. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pictogrammes

Environment
GHS09

Mention d'avertissement

Warning

Mentions de danger

H400

Conseils de prudence

P273 - P391 - P501

Classification des risques

Aquatic Acute 1

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Sandro Zambito Marsala et al.
Clinical neuropharmacology, 35(4), 185-190 (2012-07-19)
Catechol-O-methyltransferase (COMT) inhibitors are drugs commonly used in the management of patients with Parkinson disease complicated by motor fluctuations. Among them, entacapone is the most commonly used. Tolcapone has been reintroduced in patients where entacapone has proved to be ineffective
Andrew J Lees
CNS neuroscience & therapeutics, 14(1), 83-93 (2008-05-17)
The relative efficacy has not been adequately established for the two catechol-O-methyltransferase (COMT) inhibitors that are currently available for adjunctive therapy in Parkinson's disease; tolcapone and entacapone. A recent Cochrane meta-analysis of 14 studies in 2566 patients, conducted to assess
H Baas et al.
Journal of neurology, neurosurgery, and psychiatry, 63(4), 421-428 (1997-10-29)
More than 50% of patients with Parkinson's disease develop motor response fluctuations (the "wearing off" phenomenon) after more than five years of levodopa therapy. Inhibition of catechol-O-methyltransferase by tolcapone has been shown to increase levodopa bioavailability and plasma elimination half
Gillian M Keating et al.
CNS drugs, 19(2), 165-184 (2005-02-09)
Tolcapone (Tasmar) is a selective, reversible inhibitor of peripheral and central catechol-O-methyltransferase (COMT). Results of well designed studies indicate that oral tolcapone is an effective adjunct to levodopa plus a peripheral dopa-decarboxylase inhibitor (DDCI) in patients with fluctuating Parkinson's disease.
Jenny J Fischer et al.
Toxicological sciences : an official journal of the Society of Toxicology, 113(1), 243-253 (2009-09-29)
Capture compound mass spectrometry (CCMS) is a novel technology that helps understand the molecular mechanism of the mode of action of small molecules. The Capture Compounds are trifunctional probes: A selectivity function (the drug) interacts with the proteins in a
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique